Published in Circ Res on August 18, 2006
PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury? Br J Pharmacol (2007) 1.39
Is 15-min ischemia too lethal to be an ischemic preconditioning stimulus? Circ Res (2006) 0.75
Myocardial reperfusion injury. N Engl J Med (2007) 13.41
T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging (2013) 4.21
Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet (2007) 3.93
Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation (2010) 3.72
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res (2004) 3.63
Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med (2015) 3.60
Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res (2002) 2.84
Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest (2013) 2.83
Transient limb ischemia induces remote preconditioning and remote postconditioning in humans by a K(ATP)-channel dependent mechanism. Circulation (2007) 2.75
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes (2005) 2.64
Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther (2007) 2.50
Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res (2008) 2.37
Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res (2006) 2.30
Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res (2004) 2.25
Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res (2003) 2.25
Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res (2010) 2.20
Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol (2004) 2.18
Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev (2007) 2.14
Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res (2007) 2.01
The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med (2005) 1.88
Remote ischaemic preconditioning involves signalling through the SDF-1α/CXCR4 signalling axis. Basic Res Cardiol (2013) 1.88
Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol (2011) 1.74
Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis (2008) 1.74
Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res (2013) 1.72
Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol (2005) 1.71
Preconditioning protects by inhibiting the mitochondrial permeability transition. Am J Physiol Heart Circ Physiol (2004) 1.69
Effect of remote ischemic preconditioning on acute kidney injury in nondiabetic patients undergoing coronary artery bypass graft surgery: a secondary analysis of 2 small randomized trials. Am J Kidney Dis (2010) 1.68
Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. J Mol Cell Cardiol (2003) 1.68
The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol (2009) 1.66
New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation (2011) 1.66
Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J (2013) 1.65
Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes (2005) 1.62
Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart (2012) 1.56
Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart (2011) 1.55
Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol (2005) 1.54
The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol (2011) 1.53
'Conditioning' the heart during surgery. Eur J Cardiothorac Surg (2009) 1.51
Mitochondrial morphology and cardiovascular disease. Cardiovasc Res (2010) 1.51
Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res (2004) 1.46
Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther (2007) 1.45
The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol (2003) 1.44
Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse. Circ Res (2008) 1.44
The neural and humoral pathways in remote limb ischemic preconditioning. Basic Res Cardiol (2010) 1.40
Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging (2012) 1.40
Premature meta-analysis of remote ischemic preconditioning. Am J Cardiol (2009) 1.38
Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol (2007) 1.38
Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol (2010) 1.37
Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol (2003) 1.33
Hypoxia-inducible factor as a therapeutic target for cardioprotection. Pharmacol Ther (2012) 1.29
Statins and cardioprotection--more than just lipid lowering? Pharmacol Ther (2009) 1.27
Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol (2007) 1.27
Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Eur Heart J (2010) 1.26
Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol (2003) 1.23
Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther (2005) 1.22
The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med (2008) 1.21
Time to take myocardial reperfusion injury seriously. N Engl J Med (2008) 1.20
B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol (2003) 1.19
Hypoxic regulation of hand1 controls the fetal-neonatal switch in cardiac metabolism. PLoS Biol (2013) 1.18
Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech (2010) 1.18
Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol (2005) 1.18
Mitochondrial K(ATP) channels: role in cardioprotection. Cardiovasc Res (2002) 1.17
Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal (2010) 1.17
Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol (2011) 1.17
Mitochondrial dynamics in cardiovascular health and disease. Antioxid Redox Signal (2012) 1.17
Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther (2007) 1.16
PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol (2002) 1.14
p53 down-regulation: a new molecular mechanism involved in ischaemic preconditioning. FEBS Lett (2003) 1.14
Slow calcium waves and redox changes precede mitochondrial permeability transition pore opening in the intact heart during hypoxia and reoxygenation. Cardiovasc Res (2011) 1.13
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol (2009) 1.13